齐拉西酮与洛沙平治疗首发精神分裂症对照研究

目的探讨齐拉西酮与洛沙平治疗首发精神分裂症的临床疗效及安全性。方法将80例首发精神分裂症患者随机分为两组，每组40例，研究组口服齐拉西酮治疗，对照组口服洛沙平治疗，观察8周。于治疗前及治疗2周、4周、6周、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗各时段两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（P〈0．05或0．01）；治疗2周末对照组阳性症状、阴性症状因子分较研究组下降更显著（P〈0．05或0．01），其它时段评分两组均无显著性差异（Pa〉0．05）。治疗8周末，研究组显效率82．5％，总有效率92．5％；对照组分别为77．5％，87．5％。研究组主要不良反应为嗜睡、恶心、口干、头昏、失眠等，对照组主要为锥体外系反应、睡眠障碍及焦虑等。结论齐拉西酮与洛沙平治疗首发精神分裂症疗效均较显著，安全性高。

A control study of ziprasidone vs.loxapine in the treatment of first-episode schizophrenia

Objective To explore the clinical effects and safety of ziprasidone vs. loxapine in the treatment of first-episode schizophrenia. Methods 80 patients with first-episode schizophrenia were randomly assigned to two groups of 40 ones each, research group was treated with ziprasidone and control group with loxpine for 8 weeks. The clinical effects were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 2nd,4th,6th and 8th week. Results After treatment, the total and each factor scores of the PANSS of both groups lowered more sifnificantly compared with pretreatment（P〈0.05 or 0.01）, but at the end of the 2nd week positive and negative symptoms scores lowere more significantly in the control than in the research group（P〈0.05 or 0.01）, and there were no significant differences in other periods（all P〉0.05）. At the end of the 8th week, obvious and total effective rates were 82.5% and 92.5% in the research and 77.5% and 87.5% in the control group,respectively. Main adverse reactions were drowsiness, nausea, dry mouth, diziness, insomnia etc. in the research and extrapyramidal system reactions, sleep disororders,anxiety and so on in the control group. Conclusion Both ziprasidone and loxapine have evident effects and higher safety in the treatment of first-episode schizophrenia.